Pharmaceuticals
They’re Baaaaack – The Sequel
In their never-ending quest to run roughshod and exert control over the research-intensive biopharmaceutical industry, socialists in Congress have introduced various price-control bills. For some reason they continue to think innovative drugs that...
Using an International Pricing Index is NOT the Way to Lower Drug Costs
On December 6, John O’Brien, the senior advisor on drug pricing reform to Health and Human Services (HHS) Secretary Alex Azar, published a blog, entitled, “How the IPI Model Would Intro
New HHS Transparency Regulation Mandates Inaccurate Information
The Pharmaceutical Research Manufacturers Association (PhRMA), the trade association that represents the nation’s leading biopharmaceutical research companies, announced a new proposal
Importation Will Not Lower Drug Costs
Citizens Against Government Waste (CAGW) was disappointed to see that the Trump Administration announced on Thursday, July 19, that the Food and Drug Administration (FDA) is exploring ways to import lower cost
President Trump’s Blueprint to Lower Drug Costs: A Lot to Unpack
On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.
President Trump's Drug Costs Proposals Coming Soon
The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.
Stealing Patents Won’t Bring Down Drug Costs
On February 15, 2018, 18 Democratic members of Congress sent a letter to Health and Human Services (HHS) Secretary Alex Azar, asking him to use his authority under 28 U.S.C.
Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In
Report spotlights how imposing price controls and government regulations hamper drug approvals and slow competition.
Taxpayers and Patients Win First Round on 340B Drug Discount Rule
On January 1, 2018, hospitals will begin to receive lower government reimbursements for drugs purchased under the 340B program.
Rogue "Drug" Companies Face Congress
On Thursday, February 4, the House Committee on Oversight and Government Reform held a hearing entitled, “Developments in the Prescription Drug Market.”
Judge Tells Federal Agency to Obey the Law for Drug Discount Program
Taxpayers and consumers pay for misuse of the 340B program through higher insurance premiums, increased drug prices and taxes.
More of the Same
Presidential candidate and former-Secretary of State Hillary Clinton proposed several worn-out initiatives this Tuesday that would supposedly lower drug prices but, if implemented, would seriously damage research and development in the United States...
